This information is intended for use by health professionals

1. Name of the medicinal product

Stugeron 15 mg tablets

2. Qualitative and quantitative composition

Each tablet contains 15 mg cinnarizine.

Excipients with known effect:

Each tablet contains 160 mg lactose monohydrate and 15 mg sucrose.

For the full list of excipients, see section 6.1

3. Pharmaceutical form

White circular tablet with S/15 on one side and JANSSEN on the other side.

4. Clinical particulars
4.1 Therapeutic indications

Disorders of balance - maintenance therapy for symptoms of labyrinthine disorders, including vertigo, tinnitus, nystagmus, nausea and vomiting such as is seen in Meniere's Disease.

Prophylaxis of motion sickness

4.2 Posology and method of administration

Method of administration

Oral. The tablets may be chewed, sucked or swallowed whole.


Stugeron should preferably be taken after meals.

Vestibular symptoms

Adults, elderly and children over 12 years: 2 tablets three times a day.

Children 5 to 12 years: One half the adult dose.

These doses should not be exceeded.

Motion sickness

Adults, elderly and children over 12 years: 2 tablets 2 hours before you travel and 1 tablet every 8 hours during your journey.

Children 5 to 12 years: One half the adult dose.

4.3 Contraindications

Stugeron should not be given to patients with known hypersensitivity to cinnarizine.

4.4 Special warnings and precautions for use

As with other antihistamines, Stugeron may cause epigastric discomfort; taking it after meals may diminish the gastric irritation.

In patients with Parkinson's Disease, Stugeron should only be given if the advantages outweigh the possible risk of aggravating this disease.

Because of its antihistamine effect, Stugeron may prevent an otherwise positive reaction to dermal reactivity indicators if used within 4 days prior to testing.

Use of cinnarizine should be avoided in porphyria.

There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency.

Patients with rare hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, should not take this medicine because it contains lactose and sucrose.

4.5 Interaction with other medicinal products and other forms of interaction

Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of Stugeron.

4.6 Fertility, pregnancy and lactation

The safety of Stugeron in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs it is not advisable to administer Stugeron in pregnancy.

There are no data on the excretion of Stugeron in human breast milk. Use of Stugeron is not recommended in nursing mothers.

4.7 Effects on ability to drive and use machines

Stugeron may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.

4.8 Undesirable effects

The safety of Stugeron was evaluated in 303 cinnarizine-treated subjects who participated in 6 placebo-controlled trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, vertigo and control of motion sickness ; and in 937 cinnarizine-treated subjects who participated in six comparator and 13 open label clinical trials for the indications peripheral circulatory disorders, cerebral circulatory disorders and vertigo. Based on pooled safety data from these clinical trials, the most commonly reported (>1% incidence) Adverse Drug Reactions (ADRs) were: somnolence (9.9), nausea (3.0) and increased weight (1.5).

Including the above mentioned ADRs, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of Stugeron. Frequencies displayed use the following convention:

Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

System Organ Class

Adverse Drug Reactions

Frequency Category


(≥ 1/100 to < 1/10)


(≥ 1/1,000 to < 1/100)


(≥ 1/10,000 to <1/1,000)

Not Known

Nervous System Disorders



Dyskinesia; Extrapyramidal disorder; Parkinsonism; Tremor

Gastrointestinal Disorders



Upper abdominal pain Dyspepsia;

Hepato-biliary disorders

Cholestatic jaundice

Skin and subcutaneous tissue disorders


Lichenoid keratosis including Lichen planus

Subacute cutaneous lupus erythematosus

Musculoskeletal and Connective Tissue Disorders

Muscle rigidity

General Disorders and Administration Site Conditions



Weight increased

Cases of hypersensitivity, headache and dry mouth have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose


The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of cinnarizine.

Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. The most commonly reported signs and symptoms associated with overdose of cinnarizine include: alterations in consciousness ranging from somnolence to stupor and coma, vomiting, extrapyramidal symptoms, and hypotonia. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdoses involving cinnarizine.


There is no specific antidote. For any overdose, the treatment is symptomatic and supportive care.

It is advisable to contact a poison control center to obtain the latest recommendations for the management of an overdose.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC Code N07CA02.

Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine.

Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.

Vestibular eye reflexes induced by caloric stimulation of the labyrinth in guinea pigs are markedly depressed by cinnarizine.

Cinnarizine has been shown to inhibit nystagmus.

5.2 Pharmacokinetic properties

In animals, cinnarizine is extensively metabolised, N-dealkylation being the major pathway. Approximately two thirds of the metabolites are excreted with the faeces, the rest in the urine, mainly during the first five days after a single dose.


In man, after oral administration, absorption is relatively slow, peak serum concentrations occurring after 2.5 to 4 hours.


The plasma protein binding of cinnarizine is 91%.


Cinnarizine is extensively metabolised mainly via CYP2D6, but there is considerable interindividual variation in the extent of metabolism.


The reported elimination half-life for cinnarizine ranges from 4 to 24 hours.

The elimination of metabolites occurs as follows: one third in the urine (unchanged as metabolites and glucuronide conjugates) and two thirds in the faeces.

5.3 Preclinical safety data

Nonclinical safety studies showed that effects were observed only after chronic exposures that were 10 – 160 times the recommended maximum daily human dose of 100 mg/day calculated on a body surface area basis, calculated as 2 mg/kg as based on a 50 kg person. Cinnarizine blocked the cardiac hERG channel in vitro, however in isolated cardiac tissue and following intravenous application in guinea-pigs, no QTc prolongation or proarrhythmic effects were observed at substantially higher exposures than those expected clinically.

In reproductive studies in the rat, rabbit, and dog, there was no evidence of adverse effects on fertility and no teratogenicity. At high doses associated with maternal toxicity in the rat there was a decreased litter size, an increase in resorptions and a decrease in fetal birth weight.

In vitro mutagenicity studies indicated that the parent compound is not mutagenic however, after reacting with nitrite and forming the nitrosation product, a weak mutagenic activity was observed. Carcinogenicity studies have not been conducted however, no pre-neoplastic changes were evident during chronic 18-month oral administration in rats up to approximately 35 times the maximum human dose level.

6. Pharmaceutical particulars
6.1 List of excipients

Lactose monohydrate

Maize starch



Magnesium stearate

Polyvidone K90

6.2 Incompatibilities

None known.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/Aluminium foil blisters


Polystyrene tubs with polyethylene caps

Each pack containing 15, 25, 100, 250 or 1000 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Janssen-Cilag Limited

50-100 Holmers Farm Way

High Wycombe


HP12 4EG


8. Marketing authorisation number(s)

PL 00242/5009R

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 14 September 1989

Date of latest renewal: 21 August 2001

10. Date of revision of the text

May 2020